BeOne Medicines files STAR Market interim report, discloses R&D spend by product under US GAAPAug 26Quarterly updateBeiGene
FDA approves Ziihera in two regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionJazz Pharmaceuticalszanidatamab-hrii
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax
Sign inSign in